ReAlta Life Sciences

About:

ReAlta is a clinical-stage biotech company that develops a new class of drugs to address life-threatening diseases.

Website: https://realtalifesciences.com/

Top Investors: National Institute of Allergy and Infectious Diseases, Virginia Catalyst, Marathon Pharmaceuticals, Children’s Research Holdings

Description:

ReAlta Life Sciences is a clinical-stage biotech company dedicated to harnessing the power of the immune system to address life-threatening rare diseases. The company’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of hypoxic ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia.